Medical/Pharmaceuticals

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...

2023-10-25 22:33 1849

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...

2023-10-25 22:15 1721

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

SHANGHAI, Oct. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient inEurope has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination ...

2023-10-25 21:15 1691

FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic

* FDA INTERACT meeting reviews Turn Bio's ERA™ and eTurna™ technologies, approach and plans, paving way toward its IND * Company continues to pace industry's cell regeneration therapy progress MOUNTAIN VIEW, Calif., Oct. 25, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation compa...

2023-10-25 20:30 1483

ESAOTE's new S-scan Open redefines excellence in magnetic resonance imaging

GENOA, Italy, Oct. 25, 2023 /PRNewswire/ -- Esaote, a leading Italian company in ultrasound, dedicated MRI and healthcare IT,presents S-scan Open, the new configuration of S-scan,one of its best-selling MRI systems.  

2023-10-25 20:00 2019

Metabolon and Genomics England Announce Partnership to Characterize Hundreds of Rare Diseases and Advance Rare Disease Diagnosis

Alliance aims to enable the discovery of novel rare disease biomarkers to support faster diagnosis and more effective treatments MORRISVILLE, N.C., and LONDON, Oct. 25, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life sc...

2023-10-25 19:57 1169

Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell's 9MW2821 at 2023 ESMO

Shanghai, Oct. 25, 2023 /PRNewswire/ -- ESMO Congress 2023 was held in Madrid, Spain from October 20-24, the preliminary results of the Phase I/II study of 9MW2821 (Nectin-4 targeting ADC) in patients with advanced solid tumors were reported by Dr.Jian Zhang of Fudan University Shanghai Cancer Ce...

2023-10-25 17:46 1414

AMS BioteQ Makes Debut at Medical Japan 2023: Bringing Innovative Healthcare into New Horizons

TAIPEI, Oct. 25, 2023 /PRNewswire/ -- Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions, and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the ...

2023-10-25 13:06 1397

GC Cell Joins U.S Cancer Moonshot Project

Brining Expertise in NK Cell Therapy to Advance Efforts in Cancer Prevention, early detection, and treatment development ▶ New focus on NK cell therapy for conquering cancer ▶ GC Cell seizes the opportunity to share its cell gene therapy technology and capabilities globally ▶ Development of sol...

2023-10-25 11:27 1400

Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development

EAST RUTHERFORD, N.J, Oct. 25, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards inBarcelona, Spain....

2023-10-25 04:18 1679

Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma

--Industry veteran to lead growth for company's CDMO and pharmaceutical supply divisions, NovaCina and LumaCina-- MIAMI and PERTH, Australia, Oct. 25, 2023 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, announced today thatCyrus K. Mirsaidi is ...

2023-10-24 23:17 1306

Wolters Kluwer Applauded by Frost & Sullivan for Improving Healthcare Efficiencies, Quality, and Outcomes and for Its Competitive Strategies

Wolters Kluwer uniquely leverages its expertise to meet market and customer needs, positioning it to capitalize on new growth opportunities and lead in healthcare conversational AI. SAN ANTONIO, Oct. 24, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the conversational artificial inte...

2023-10-24 21:30 1272

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

* Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in theJournal of Clinical Oncology and accepted by ESMO for oral presentation SEOUL, South Korea, Oct. 24, 2023 /PRNewswir...

2023-10-24 21:00 1400

Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO

HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...

2023-10-24 20:00 1102

OrbiMed Raises $4.3 Billion Across Private Investment Funds

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- OrbiMed, a global healthcare investment firm, is pleased to announce it has raised more than$4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit O...

2023-10-24 19:30 1354

Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China

First Amyloid PET Tracer Received Regulatory Approval in China BERLIN and BEIJING, Oct. 24, 2023 /PRNewswire/ -- Life Molecular Imaging (LMI) and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® (with Chinese trade name 欧韦宁®, florbetaben F-18 injection) has received regulatory appr...

2023-10-24 16:00 1236

Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval

SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "BioRay") announced onOctober 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration (FDA). This marks BioRay's first ...

2023-10-24 15:05 1060

Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair

TAIZHOU, China, Oct. 24, 2023 /PRNewswire/ -- From October 19 to 22, the 14th China (Taizhou) International Pharmaceutical Fair, sponsored by the China Chamber of International Commerce and hosted by the Taizhou Municipal People's Government andJiangsu Branch of the China Council for the Promotio...

2023-10-24 13:39 1545

OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product

Visit OBiO at ESGCT 30th Annual Congress in Brussels SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene...

2023-10-24 12:05 1277

Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards

SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- Juniper Biologics , a global science-led pharmaceutical company headquartered inSingapore, has been honored with the prestigious title of the "Most Innovative Oncology Pharmaceutical Company 2023" by the Global Health & ...

2023-10-24 12:00 1221
1 ... 62636465666768 ... 577